by
Sean Ruck, Contributing Editor | March 23, 2018
From the March 2018 issue of HealthCare Business News magazine
Another prostate cancer-related study had a direct comparison of clinical outcomes between cohorts of cancer patients treated with IMRT and proton therapy. The investigators from the University of Florida Health Proton Therapy Institute and the Mayo Clinic in Arizona found similar complication rates between IMRT and proton therapy, but significantly higher disease control rates with proton therapy for low- and intermediate-risk prostate cancer patients.
Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
HCB News: With about five months under your belt, how is the association doing?
SW: The association is doing well and growing. Two members treated their first patients in 2017, which is always exciting because it opens new markets to cancer patients that didn’t have access to proton therapy previously. If proton therapy is accessible in cities where cancer patients live, it eliminates the need to travel away from home and/or their family, which is important for them while receiving cancer treatment.
HCB News: What can attendees expect at this month's show?
SW: I think we have a great conference planned which will focus on improving access through education, awareness and outcomes. We’ll be discussing alternative payment models, patient advocacy, legislative efforts, marketing and new technology. If a health system is considering proton therapy, this is the one conference they need to attend.
Back to HCB News
